Osteocalcin, a promising marker of osteoporosis: evaluation in post-menopausal females with osteoporosis

M. Faiyaz Alam, M. Azmat Rana, M. Shamshad Alam


Background: Osteocalcin, has high affinity for calcium. In osteoporotic women, deficiency of calcium may lead to lowering of the formation of hydroxyapatite crystals. Thus, in the state of hypo mineralization, free osteocalcin available in the circulation. Therefore, present study was designed to evaluate significance of serum osteocalcin in diagnosis of osteoporosis, and relationship between Serum Osteocalcin and BMD (Bone mineral Density) in post-menopausal females with osteoporosis and without osteoporosis.

Methods: One hundred and forty seven post-menopausal women between age 45 to 80 years attending the hospital OPD were studied. To be eligible for the study they had to have been postmenopausal for at least one year. The diagnosis of osteoporosis was made based on T-Scores (BMD) at the lumber spine (L1 to L4 and femaral neck) by DEXA (GE lunar Densitometer). Serum osteocalcin level was estimated by LIAISON osteocalcin assay. Patients with chronic conditions affecting skeletal health and patients on drugs affecting the skeleton were excluded from the study.

Results: Serum osteocalcin level in post-menopausal female without osteoporosis was 9.87±1.04ng/ml, while post-menopausal female with osteoporosis had 22.62±2.25ng/ml suggesting significant increase in bone marker level in osteoporotic females (p<0.05.) Correlation study between BMD and osteocalcin showed strong Negative Correlation (r=-0.77, p<0.05).

Conclusions: Serum osteocalcin can be considered as a specific marker of osteoblast function as its levels have been shown to correlate with bone formation rates. Thus, serum osteocalcin can be used for diagnosis and monitoring of response to therapy and this may be the better predictor than BMD.


Bone mineral density, Mineralization, Osteocalcin, Postmenopausal osteoporosis

Full Text:



Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate therapy: bone histomorphometry and clinical correlates. J Bone Miner Res. 1994;9(1):136.

Moyad MA. Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests. Urologic clini North Ameri. 2004;31(2):321-30.

Neetakumar AA, Tandon N, Goswami R, Dineshkumar SA. Ethnic variation of host and risk factors in silent epidemic of osteoporosis. Orthoped Tod. 2004;6(4):240-4.

Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. J bone mine res. 1999;14(9):1622-7.

Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, et al. Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteopo internat. 2004;15(12):981-91.

Looker AC, Bauer DC, Chesnut Iii CH, Gundberg CM, Hochberg MC, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteopo Inter. 2000;11(6):467-80.

Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clinic Endocrinol Metabo. 2005;90(5):2762-7.

Gundberg CM, Nishimoto SK. Vitamin K dependent proteins of bone and cartilage. Dynam of bone cartil metabo. 2006:55-70.

Ivaska KK, Pettersson K, Nenonen A, Uusi-Rasi K, Heinonen A, Kannus P, et al. Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clini chemis. 2005;51(12):2362-5.

Del Pino J, Martin-Gomez E, Martin-Rodriguez M, Lopez-Sosa C, Cordero M, Lanchares JL, et al. Influence of sex, age, and menopause in serum osteocalcin (BGP) levels. Klini Wochen. 1991;69(24):1135-8.

Ones K, Schacht E, Dukas L, Cagler N. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: A two years, randomized, multiarm, controlled trial. Inter J Epidemiol. 2007;4(4):1-9.

Yasumura S, Aloia JF, Gundberg CM, YEH J, Vaswani AN, Yuen K, Monte AF, et al. Serum osteocalcin and total body calcium in normal pre-and postmenopausal women and postmenopausal osteoporotic patients. J Clini Endocrinol Metabo. 1987;64(4):681-5.

Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clini Chemist. 1995;41(10):1439-45.

Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Europ J Clini Investi. 1988;18(2):191-5.

Slemenda CH, Hui SL, Longcope CH, Johnston CC. Sex steroids and bone mass. A study of changes about the time of menopause. J clini investi. 1987;80(5):1261-9.

Pirro M, Leli C, Fabbriciani G, Manfredelli MR, Callarelli L, Bagaglia F, et al. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteopo internat. 2010;21(2):297-306.

Hari kumar KV, Muthukrishnan J, Verma A, Modi KD. Correlation between bone markers and bone mineral density in postmenopausal Women with osteoporosis. Depart Endocrinol , Medwin; 2008.